Menu
Recruiting NCT07121335

SMC Radiation Oncology SABR Cohort for Oligometastasis

— Observational Stereotactic Body Radiation Therapy (SBRT) Oligometastasis Oligoprogression ctDNA

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Stereotactic body radiotherapy (SBRT).
Who it may be relevant to
Registry conditions: Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer

Overview

The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.

Interventions

  • Radiation Stereotactic body radiotherapy (SBRT)
    Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).

Primary outcome measures

  • Progression-free survival [Time frame: From start of SABR to the earliest of local failure, distant failure, death, or last follow-up. It will be measured at 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.]
  • Physician assessed toxicity [Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.]
  • Patient-reported outcome [Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.]
  • Local failure [Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.]
  • Dynamics of ctDNA [Time frame: It will be collected 1-week before SABR and 4-6 weeks after SABR.]

Eligibility criteria

Inclusion criteria

  • Performance status (ECOG PS) 0-2
  • Diagnosed with metastatic disease
  • Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)

Exclusion criteria

  • Patient with a history of prior radiotherapy to the site planned for SABR
  • Patients with concomitant brain metastases

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

South Korea · 1 center
  • Samsung medical center — Seoul

Identifiers

NCT: NCT07121335 · SMC 2025-03-037

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗